The heart of the matter

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3794-3796

  Portera, Chia C ^a   Swain, Sandra M ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LETROZOLE; METHOTREXATE; RAZOXANE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; HER 2 PEPTIDE E75 (369 377), HUMAN; HER-2 PEPTIDE E75 (369-377), HUMAN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG INDUCED DISEASE; EDITORIAL; ETHNICITY; HEART MUSCLE ISCHEMIA; HUMAN; LONG TERM CARE; MEDICARE; PRIORITY JOURNAL; AGED; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; FEMALE; METABOLISM; NOTE;

AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; PEPTIDE FRAGMENTS;

EID: 34548537219     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9537     Document Type: Editorial

References (21)

1. Pinder MC, Zhigang D, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007
2. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005
3. McCarthy EP, Iezzoni LI, Davis RB, et al: Does clinical evidence support ICD-9-CM diagnosis coding of complications? Med Care 38:868-876, 2000
4. Warren JL, Harlan LC, Fahey A, et al: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:IV-55-61, 2002
5. Bach PB, Guadagnoli E, Schrag D, et al: Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40:IV-19-25, 2002
6. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879, 2003
7. Hooning MJ, Botma A, Aleman BM, et al: Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99:365-375, 2007
8. Jensen BV, Skovsgaard T, Nielsen SL: Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13:699-709, 2002
9. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007
10. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
11. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153, 2004
12. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25:493-500, 2007
13. Wouters KA, Kremer LC, Miller TL, et al: Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haematol 131:561-578, 2005
14. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
15. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
16. Paik S, Bryant J, Park C, et al: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
17. Järvinen TA, Liu ET: Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes: Molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6:579-602, 2006
18. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005
19. Tanner M, Isola J, Wiklund T, et al: Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group trial 9401. J Clin Oncol 24:2428-2436, 2006
20. Slamon DJ: Phase III trail comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: Second interim efficacy analysis. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006
21. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006